[Special Stock] Neopharm Sells Out Immediately Upon Olive Young Entry... Zeroid Expected to Be the 'Second Genic'

Neopharm is showing strong performance. The medical skincare brand ZEROID's initial stock was sold out within a day of entering Olive Young, which appears to be influencing the stock price. Recently, in the domestic stock market, Zenic's stock price tripled in 12 trading days, boosted by the popularity of the 'Biodern Sun Bio Collagen Real Deep Mask.' Interest in listed companies owning popular cosmetics has increased.

At 9:44 a.m. on the 10th, Neopharm was trading at 23,800 KRW, up 10.7% from the previous day.

ZEROID, holding the title of 'No.1 Hospital Cosmetics,' began sales at major Olive Young stores and its official online mall on the 26th to expand consumer contact points. Since its launch in 2002, ZEROID has been stocked in about 70% of dermatology clinics and 80% of pediatric clinics nationwide. ZEROID introduced signature products such as 'Intensive Cream,' 'Intensive Hydrating Ampoule,' and 'Soothing Cream' for sensitive skin.

ZEROID reported that during the Olive Young showcase live broadcast on the day of entry, it exceeded its sales target by approximately 300%. The 'Intensive Cream,' 'Soothing Cream,' and 'Foaming Cleanser' products sold out their initial online stock, attracting consumer attention. Due to the enthusiastic response, giveaway gifts for customers purchasing during the live broadcast were depleted about 9 minutes after the broadcast started.

A ZEROID representative said, "We are pleased to achieve the feat of having ZEROID as the best-selling product across the entire Olive Young online mall simultaneously with the Olive Young launch," adding, "Thanks to the high interest from customers, we were able to exceed our sales target by about 200% during the showcase promotion period that continued until the 27th." They added, "We will continue to repay the love we have received with abundant benefits and promotions."